

Reference:	FOI.4540.20
Subject:	Prostate and ovarian cancer
Date of Request:	17 November 2020

Requested:

1. How many patients were diagnosed with prostate cancer over the last 3 months? Of these, how many patients were diagnosed with metastatic prostate cancer?
2. How many prostate cancer patients were treated over the last 3 months with:
 - a. Docetaxel
 - b. Abiraterone
 - c. Enzalutamide
 - d. Cabazitaxel
3. How many patients have been diagnosed with advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer ovarian cancer patients to another trust, if so which one?
4. Of the ovarian cancer patients diagnosed over the last 3 months, how many have been treated with:
 - a. Paclitaxel in combination with a platinum-based compound
 - b. Platinum-based therapy alone (cisplatin or carboplatin)
 - c. Bevacizumab in combination with paclitaxel and carboplatin
 - d. Olaparib
 - e. Niraparib
 - f. Rucaparib
5. Of the ovarian cancer patients diagnosed over the last 3 months, how many have been tested for the BRCA mutation? And of these, how many tested positive?
6. Of the ovarian cancer patients who were positive for a BRCA mutation, how many patients received
 - a. Olaparib for 1st line maintenance
 - b. Bevacizumab in combination with paclitaxel and carboplatin for 1st line maintenance

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested for questions 5 and 6, as it is estimated that the cost of answering your request would exceed the "appropriate level" as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. The "appropriate level" represents the estimated cost of one person spending 18 hours or (2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the information requested, the UHB would be required to conduct a manual trawl of all cancer patients' medical records, for the period requested, to establish if any patients were tested for the BRCA mutation and identify any treatments received.

Therefore, the UHB is applying an exemption under Section 12 of the Freedom of Information Act 2000 (the FOI) to questions 5 and 6, which provides an exemption from a public authority's obligation to comply with a request for information, where the cost of compliance is estimated to exceed the appropriate limit.

Under section 16 of the FOI, we are required as a public authority, to provide advice and assistance so far as it is reasonable, to individuals who have made a request under the FOI and therefore can provide you with some of the information requested.

1. Hywel Dda University Health Board (UHB) confirms that one hundred and three (103) patients were diagnosed with prostate cancer, with six (6) of those diagnosed with metastatic prostate cancer, during the period 1 August to 31 October 2020.
2. The UHB provides, within the table overleaf, the number of prostate cancer patients treated with the listed medications, during the period 1 August to 31 October 2020.

Medication	Number of patients
Docetaxel	28
Abiraterone	14
Enzalutamide	32
Cabazitaxel	*

3. The UHB confirms that eleven (11) patients have been diagnosed with ovarian cancer, during the period 1 August to 31 October 2020.
4. The UHB provides, within the table below, the number of ovarian cancer patients treated with the listed medications, during the period 1 August to 31 October 2020.

Medication	Number of patients
Paclitaxel in combination with a platinum-based compound	11
Platinum-based therapy alone (cisplatin or carboplatin)	9
Bevacizumab in combination with paclitaxel and carboplatin	0
Olaparib	*
Niraparib	0
Rucaparib	0

Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 2018/ General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles

6 and 9 of the GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 defines personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.